Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

Samankaltaisia teoksia

• Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
  Tekijä: Tai, Wanbo, et al.
  Julkaistu: (2020)
• The spike protein of SARS-CoV — a target for vaccine and therapeutic development
  Tekijä: Du, Lanying, et al.
  Julkaistu: (2009)
• Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
  Tekijä: Du, Lanying, et al.
  Julkaistu: (2013)
• Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
  Tekijä: Jiang, Shibo, et al.
  Julkaistu: (2020)
• Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
  Tekijä: Jiang, Shibo, et al.
  Julkaistu: (2020)